MORGAN STANLEY PLC/CALL/INCYTE CO./70/0.5/20.12.24 | Real-time Bid/Ask 09:19:06 2024-07-11 am EDT | ||
| 1.05 EUR / 1.17 EUR | +16.84% |
|
| 1 month | -12.61% | ||
| 3 months | +13.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.03 | +8.42% |
| 24-07-10 | 1.04 | +9.47% |
| 24-07-09 | 0.95 | +15.85% |
| 24-07-08 | 0.82 | +9.33% |
| 24-07-05 | 0.75 | +7.14% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 08:09 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9H30 |
| ISIN | DE000ME9H304 |
| Date issued | 2024-03-01 |
| Strike | 70 $ |
| Maturity | 2024-12-20 (162 Days) |
| Parity | 2 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.73 € |
|---|---|
| Lowest since issue | 0.45 € |
| Spread | 0.12 € |
| Spread % | 10.34% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
60.73
USD
Average target price
72.66
USD
Spread / Average Target
+19.65%
- Stock Market
- Warrants
- Warrant
